Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Summary

The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

Timeline

Start

2015-04

Primary completion

2022-12

Completion

2022-12

Publications

• Results Rindone G, Aroldi A, Bossi E, Verga L, Zambrotta G, Tarantino S, Piazza R, Mussolin L, Chiarle R, Gambacorti-Passerini C. A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas. Blood Adv. 2023 Feb 14;7(3):314-316. doi: 10.1182/bloodadvances.2022007538. No abstract available.

Drugs

Indications